

SANDERLING V LTD PARTNERSHIP
 Form 3
 April 10, 2013

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Expires: January 31, 2015
 Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *			2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â Sanderling Venture Partners V, LP			(Month/Day/Year)	CHIMERIX INC [CMRX]	
(Last)	(First)	(Middle)		4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
400 SOUTH EL CAMINO REAL,Â SUITE 1200				(Check all applicable)	
(Street)				<input type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner	6. Individual or Joint/Group Filing(Check Applicable Line)
SAN MATEO,Â CAÂ 94402				<input type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below)	<input type="checkbox"/> Form filed by One Reporting Person
(City)	(State)	(Zip)			<input checked="" type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	112,674	I	SEE FOOTNOTE ⁽¹⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	---	---	--	---

Edgar Filing: SANDERLING V LTD PARTNERSHIP - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Series A Preferred Stock	Â (2)	Â (2)	Common Stock	183,096	\$ (2)	I	SEE FOOTNOTE (1)
Series B Preferred Stock	Â (3)	Â (3)	Common Stock	474,330	\$ (3)	I	SEE FOOTNOTE (1)
Series B-1 Preferred Stock	Â (4)	Â (4)	Common Stock	469,480	\$ (4)	I	SEE FOOTNOTE (1)
Series C Preferred Stock	Â (5)	Â (5)	Common Stock	695,496	\$ (5)	I	SEE FOOTNOTE (1)
Series D Preferred Stock	Â (6)	Â (6)	Common Stock	771,372	\$ (6)	I	SEE FOOTNOTE (1)
Series E Preferred Stock	Â (7)	Â (7)	Common Stock	619,852	\$ (7)	I	SEE FOOTNOTE (1)
Series F Preferred Stock	Â (8)	Â (8)	Common Stock	792,037	\$ (8)	I	SEE FOOTNOTE (1)
Warrants	Â (9)	02/11/2018	Common Stock	198,008	\$ 7.26	I	SEE FOOTNOTE (1)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Sanderling Venture Partners V, LP 400 SOUTH EL CAMINO REAL SUITE 1200 SAN MATEO, CA 94402	Â	Â X	Â	Â
SANDERLING V BIOMEDICAL LP Â	Â	Â X	Â	Â
SANDERLING V LTD PARTNERSHIP 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	Â X	Â	Â
SANDERLING V BETEILIGUNGS GMBH & CO KG 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	Â X	Â	Â
SANDERLING VENTURES MANAGEMENT V 400 SOUTH EL CAMINO REAL STE 1200 SAN MATEO, CA 94402-1708	Â	Â X	Â	Â
	Â	Â X	Â	Â

SANDERLING V BIOMEDICAL CO INVESTMENT FUND LP
 400 SOUTH EL CAMINO REAL
 STE 1200
 SAN MATEO, CA 94402-1708

Sanderling Venture Partners V Co Investment Fund, LP
 400 SOUTH EL CAMINO REAL
 SUITE 1200
 SAN MATEO, CA 94402

^ ^ X ^ ^

Sanderling V Strategic Exit Fund LP
 400 SOUTH EL CAMINO REAL
 SUITE 1200
 SAN MATEO, CA 94402

^ ^ X ^ ^

Sanderling Venture Partners VI Co Investment Fund LP
 400 SOUTH EL CAMINO REAL STE 1200
 SAN MATEO, CA 94402-1708

^ ^ X ^ ^

Sanderling VI Beteiligungs GmbH & Co KG
 400 SOUTH EL CAMINO REAL, SUITE 1200
 SAN MATEO, CA 94402

^ ^ X ^ ^

Signatures

See Signatures Included in
 Exhibit 99.2

04/10/2013

**Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) See attached Exhibit 99.1.

The Series A Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series A Preferred Stock, for no additional consideration.

(2) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series A Preferred Stock, for no additional consideration.

The Series B Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B Preferred Stock, for no additional consideration.

(3) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B Preferred Stock, for no additional consideration.

The Series B-1 Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B-1 Preferred Stock, for no additional consideration.

(4) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series B-1 Preferred Stock, for no additional consideration.

The Series C Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series C Preferred Stock, for no additional consideration.

(5) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series C Preferred Stock, for no additional consideration.

The Series D Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series D Preferred Stock, for no additional consideration.

(6) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series D Preferred Stock, for no additional consideration.

The Series E Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series E Preferred Stock, for no additional consideration.

(7) convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series E Preferred Stock, for no additional consideration.

The Series F Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series F Preferred Stock, for no additional consideration.

(8) The Series F Preferred Stock has no expiration date and is convertible at any time at the option of the holder and will automatically convert upon the closing of the Issuer's initial public offering, at a conversion ratio of 1 share of Common Stock for every 3.55 shares of Series F Preferred Stock, for no additional consideration.

Edgar Filing: SANDERLING V LTD PARTNERSHIP - Form 3

Series F Preferred Stock, for no additional consideration.

(9) The warrants are immediately exercisable.

^

Remarks:

Form 3 filing 1 of 2. See Form 3 filing 2 of 2 for additional members of this joint filing.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.